Capital International Investors lowered its stake in Johnson & Johnson (NYSE:JNJ) by 25.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 14,722,277 shares of the company’s stock after selling 4,898,022 shares during the period. Capital International Investors’ holdings in Johnson & Johnson were worth $2,147,538,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Ilmarinen Mutual Pension Insurance Co bought a new stake in shares of Johnson & Johnson during the third quarter worth $31,646,000. UMA Financial Services Inc. bought a new stake in Johnson & Johnson in the 3rd quarter worth about $431,000. Voya Financial Advisors Inc. grew its position in Johnson & Johnson by 0.5% in the 3rd quarter. Voya Financial Advisors Inc. now owns 78,872 shares of the company’s stock worth $10,143,000 after purchasing an additional 387 shares in the last quarter. Endurant Capital Management LP bought a new stake in Johnson & Johnson in the 3rd quarter worth about $13,897,000. Finally, Merit Financial Group LLC grew its position in Johnson & Johnson by 5.2% in the 3rd quarter. Merit Financial Group LLC now owns 8,633 shares of the company’s stock worth $1,117,000 after purchasing an additional 427 shares in the last quarter. Institutional investors and hedge funds own 69.30% of the company’s stock.
JNJ has been the subject of a number of recent analyst reports. Credit Suisse Group reduced their price objective on shares of Johnson & Johnson from $170.00 to $159.00 and set an “outperform” rating for the company in a research report on Friday, March 6th. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $158.00 target price for the company in a research report on Wednesday, December 18th. Citigroup initiated coverage on shares of Johnson & Johnson in a research report on Wednesday, March 4th. They set a “buy” rating and a $163.00 target price for the company. Morgan Stanley raised shares of Johnson & Johnson from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $145.00 to $170.00 in a research report on Tuesday, December 17th. Finally, Wells Fargo & Co increased their target price on shares of Johnson & Johnson from $155.00 to $165.00 and gave the company an “overweight” rating in a research report on Thursday, January 9th. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $162.33.
Shares of Johnson & Johnson stock traded up $5.37 on Thursday, hitting $124.77. 5,327,248 shares of the company traded hands, compared to its average volume of 15,986,437. The firm’s 50-day simple moving average is $140.69 and its 200 day simple moving average is $138.34. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 0.45. The company has a market cap of $314.20 billion, a P/E ratio of 18.40, a P/E/G ratio of 1.99 and a beta of 0.74. Johnson & Johnson has a 12-month low of $109.16 and a 12-month high of $154.50.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $1.88 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.01. The firm had revenue of $20.75 billion for the quarter, compared to analysts’ expectations of $20.83 billion. Johnson & Johnson had a net margin of 22.18% and a return on equity of 39.27%. The business’s quarterly revenue was up 1.7% on a year-over-year basis. During the same quarter last year, the company posted $1.97 EPS. Analysts predict that Johnson & Johnson will post 9.03 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Tuesday, February 25th were given a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a yield of 3.05%. The ex-dividend date of this dividend was Monday, February 24th. Johnson & Johnson’s payout ratio is presently 43.78%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: What are retained earnings?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.